Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MURA – Mural Oncology plc

Float Short %

4.8

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

1.4

EPS Last/This Y

1.92

EPS This/Next Y

3.88

Price

2.08

Target Price

6

Analyst Recom

2

Performance Q

-17.79

Relative Volume

0.31

Beta

3.02

Ticker: MURA




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15MURA1.770.710.0932668
2025-08-18MURA1.830.680.0332947
2025-08-19MURA1.8050.660.0033758
2025-08-20MURA2.0850.650.1034011
2025-08-21MURA2.070.290.1230734
2025-08-22MURA2.080.280.0130458
2025-08-25MURA2.060.280.0130458
2025-08-26MURA2.060.28999.9930481
2025-08-27MURA2.070.280.0030490
2025-08-28MURA2.080.280.0030505
2025-08-29MURA2.060.280.0030505
2025-09-02MURA2.080.280.0030510
2025-09-03MURA2.080.280.0030510
2025-09-04MURA2.080.280.0030510
2025-09-05MURA2.080.280.0030510
2025-09-08MURA2.080.280.0030510
2025-09-09MURA2.080.280.0030510
2025-09-10MURA2.070.280.0030510
2025-09-11MURA2.070.280.0030510
2025-09-12MURA2.080.280.0030510
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15MURA1.77- - -5.66
2025-08-18MURA1.83- - -5.66
2025-08-19MURA1.8068.5- -5.66
2025-08-20MURA2.0968.5- -5.66
2025-08-21MURA2.0868.5- -5.66
2025-08-22MURA2.0868.5- -5.66
2025-08-25MURA2.0768.5- -5.66
2025-08-26MURA2.0668.5- -5.66
2025-08-28MURA2.0768.5- -5.66
2025-08-29MURA2.0768.5- -5.66
2025-09-02MURA2.0868.5- -5.66
2025-09-03MURA2.0868.5- -5.66
2025-09-04MURA2.0868.5- -5.66
2025-09-05MURA2.0768.5- -5.66
2025-09-08MURA2.0768.5- -5.66
2025-09-09MURA2.0868.5- -5.66
2025-09-10MURA2.0768.5- -5.66
2025-09-11MURA2.0768.5- -5.66
2025-09-12MURA2.0868.5- -5.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15MURA-0.7923.472.01
2025-08-18MURA-0.7929.242.01
2025-08-19MURA-0.7929.242.00
2025-08-20MURA-0.8029.242.00
2025-08-21MURA-0.8029.242.00
2025-08-22MURA-0.8029.242.00
2025-08-25MURA-0.80-2.592.00
2025-08-26MURA-0.52-2.592.00
2025-08-27MURA-0.52-2.591.64
2025-08-28MURA-0.52-2.591.64
2025-08-29MURA-0.52-2.591.64
2025-09-02MURA-0.52-2.591.64
2025-09-03MURA-0.52-2.591.64
2025-09-04MURA-0.52-2.591.64
2025-09-05MURA-0.52-2.591.64
2025-09-08MURA-0.37-2.591.64
2025-09-09MURA-0.37-2.591.64
2025-09-10MURA-0.37-2.591.64
2025-09-11MURA-0.37-2.594.80
2025-09-12MURA-0.37-2.594.80
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.77

Avg. EPS Est. Current Quarter

-0.59

Avg. EPS Est. Next Quarter

-0.37

Insider Transactions

-0.37

Institutional Transactions

-2.59

Beta

3.02

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

Sentiment Score

57

Actual DrawDown %

87.8

Max Drawdown 5-Year %

Target Price

6

P/E

Forward P/E

PEG

P/S

P/B

0.61

P/Free Cash Flow

EPS

-8.58

Average EPS Est. Cur. Y​

-5.66

EPS Next Y. (Est.)

-1.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.31

Return on Equity vs Sector %

-275.2

Return on Equity vs Industry %

-262.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-2.28

EBIT Estimation

Mural Oncology plc
Sector: Healthcare
Industry: Biotechnology
Employees: 116
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
stock quote shares MURA – Mural Oncology plc Stock Price stock today
news today MURA – Mural Oncology plc stock forecast ,stock prediction 2023 2024 2025
marketwatch MURA – Mural Oncology plc yahoo finance google finance
stock history MURA – Mural Oncology plc invest stock market
stock prices MURA premarket after hours
ticker MURA fair value insiders trading

MDT – Medtronic Plc

Float Short %

1.03

Margin Of Safety %

7

Put/Call OI Ratio

0.68

EPS Next Q Diff

0.09

EPS Last/This Y

0.14

EPS This/Next Y

0.44

Price

94.05

Target Price

98.33

Analyst Recom

2.18

Performance Q

6.26

Relative Volume

1

Beta

0.79

Ticker: MDT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15MDT930.951.39211633
2025-08-18MDT92.830.951.11172927
2025-08-19MDT89.921.060.63246845
2025-08-20MDT93.220.910.33258996
2025-08-21MDT91.110.870.65268297
2025-08-22MDT92.70.860.52269374
2025-08-25MDT92.020.572.09200882
2025-08-26MDT92.180.600.85206441
2025-08-27MDT92.040.601.57209434
2025-08-28MDT91.970.610.54211470
2025-08-29MDT92.810.620.62215803
2025-09-02MDT93.320.611.44210298
2025-09-03MDT92.240.660.98220575
2025-09-04MDT92.840.670.22224924
2025-09-05MDT92.890.670.87226739
2025-09-08MDT930.660.43222415
2025-09-09MDT94.060.670.32224773
2025-09-10MDT92.340.670.82228182
2025-09-11MDT94.270.670.77231163
2025-09-12MDT94.060.680.47235081
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15MDT93.00-0.1921.55.55
2025-08-18MDT92.83-0.1840.35.55
2025-08-19MDT89.90-0.1658.85.55
2025-08-20MDT93.22-0.11081.05.55
2025-08-21MDT91.11-0.1497.45.55
2025-08-22MDT92.694.3787.35.63
2025-08-25MDT92.034.3637.95.63
2025-08-26MDT92.184.3691.45.63
2025-08-27MDT92.044.3894.65.63
2025-08-28MDT91.954.3897.35.63
2025-08-29MDT92.714.3954.95.63
2025-09-02MDT93.324.3895.55.63
2025-09-03MDT92.244.3788.75.63
2025-09-04MDT92.844.3900.85.63
2025-09-05MDT92.904.3864.45.63
2025-09-08MDT92.994.3867.15.63
2025-09-09MDT94.074.3933.45.63
2025-09-10MDT92.354.3747.65.63
2025-09-11MDT94.254.3990.55.63
2025-09-12MDT94.054.3848.05.63
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15MDT0.000.420.91
2025-08-18MDT0.00-0.150.91
2025-08-19MDT0.00-0.150.91
2025-08-20MDT0.00-0.150.91
2025-08-21MDT0.00-0.150.91
2025-08-22MDT0.00-0.150.91
2025-08-25MDT0.000.130.91
2025-08-26MDT0.300.130.91
2025-08-27MDT0.300.131.10
2025-08-28MDT0.300.131.10
2025-08-29MDT0.300.131.10
2025-09-02MDT0.300.161.10
2025-09-03MDT0.360.161.10
2025-09-04MDT0.360.161.10
2025-09-05MDT-0.250.161.10
2025-09-08MDT-0.250.131.10
2025-09-09MDT-0.250.131.10
2025-09-10MDT-0.250.131.10
2025-09-11MDT-0.250.131.03
2025-09-12MDT-0.250.131.03
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.26

Avg. EPS Est. Current Quarter

1.31

Avg. EPS Est. Next Quarter

1.35

Insider Transactions

-0.25

Institutional Transactions

0.13

Beta

0.79

Average Sales Estimate Current Quarter

8855

Average Sales Estimate Next Quarter

8845

Fair Value

100.17

Quality Score

85

Growth Score

82

Sentiment Score

22

Actual DrawDown %

30.8

Max Drawdown 5-Year %

-45.1

Target Price

98.33

P/E

25.96

Forward P/E

15.47

PEG

4.39

P/S

3.53

P/B

2.52

P/Free Cash Flow

22.74

EPS

3.62

Average EPS Est. Cur. Y​

5.63

EPS Next Y. (Est.)

6.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.63

Relative Volume

1

Return on Equity vs Sector %

-15.1

Return on Equity vs Industry %

-8.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.07

EBIT Estimation

848
Medtronic plc.
Sector: Healthcare
Industry: Medical Devices
Employees: 95000
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
stock quote shares MDT – Medtronic Plc Stock Price stock today
news today MDT – Medtronic Plc stock forecast ,stock prediction 2023 2024 2025
marketwatch MDT – Medtronic Plc yahoo finance google finance
stock history MDT – Medtronic Plc invest stock market
stock prices MDT premarket after hours
ticker MDT fair value insiders trading

ITRM – Iterum Therapeutics Plc

Float Short %

2.79

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.17

EPS Last/This Y

0.93

EPS This/Next Y

0.25

Price

0.68

Target Price

7

Analyst Recom

1

Performance Q

-31.48

Relative Volume

1.53

Beta

3.25

Ticker: ITRM




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15ITRM0.87N/AN/A0
2025-08-18ITRM0.87N/AN/A0
2025-08-19ITRM0.83N/AN/A0
2025-08-20ITRM0.7556N/AN/A0
2025-08-21ITRM0.75N/AN/A0
2025-08-22ITRM0.7439N/AN/A0
2025-08-25ITRM0.7201N/AN/A0
2025-08-26ITRM0.6855N/AN/A0
2025-08-27ITRM0.72N/AN/A0
2025-08-28ITRM0.69N/AN/A0
2025-08-29ITRM0.6899N/AN/A0
2025-09-02ITRM0.6422N/AN/A0
2025-09-03ITRM0.629N/AN/A0
2025-09-04ITRM0.639N/AN/A0
2025-09-05ITRM0.6747N/AN/A0
2025-09-08ITRM0.6603N/AN/A0
2025-09-09ITRM0.7002N/AN/A0
2025-09-10ITRM0.6943N/AN/A0
2025-09-11ITRM0.7098N/AN/A0
2025-09-12ITRM0.6825N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15ITRM0.86- 6.80.00
2025-08-18ITRM0.86- 7.30.00
2025-08-19ITRM0.83- 7.70.00
2025-08-20ITRM0.75- 8.00.00
2025-08-21ITRM0.75- 7.50.00
2025-08-22ITRM0.74- 7.4-0.33
2025-08-25ITRM0.72- 7.5-0.33
2025-08-26ITRM0.68- 7.7-0.33
2025-08-28ITRM0.69- 7.6-0.33
2025-08-29ITRM0.68- 7.4-0.33
2025-09-02ITRM0.64- 7.7-0.33
2025-09-03ITRM0.63- 21.1-0.33
2025-09-04ITRM0.63- 21.1-0.33
2025-09-05ITRM0.68- 21.1-0.33
2025-09-08ITRM0.66- 21.1-0.33
2025-09-09ITRM0.71- 21.1-0.33
2025-09-10ITRM0.69- 21.1-0.33
2025-09-11ITRM0.71- 21.1-0.33
2025-09-12ITRM0.68- 21.1-0.33
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15ITRM1.56-4.614.76
2025-08-18ITRM1.56-6.314.76
2025-08-19ITRM1.56-6.314.76
2025-08-20ITRM1.56-6.314.76
2025-08-21ITRM1.56-6.314.76
2025-08-22ITRM1.56-6.314.76
2025-08-25ITRM1.5649.414.76
2025-08-26ITRM1.5649.414.76
2025-08-27ITRM1.5649.413.59
2025-08-28ITRM1.5649.413.59
2025-08-29ITRM1.5649.413.59
2025-09-02ITRM1.5649.413.59
2025-09-03ITRM1.5649.413.59
2025-09-04ITRM1.5649.413.59
2025-09-05ITRM1.5649.413.59
2025-09-08ITRM1.5649.413.59
2025-09-09ITRM1.5649.413.59
2025-09-10ITRM1.5649.413.59
2025-09-11ITRM1.5649.412.79
2025-09-12ITRM1.5649.412.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.09

Avg. EPS Est. Next Quarter

0.01

Insider Transactions

1.56

Institutional Transactions

49.41

Beta

3.25

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

3

Growth Score

21

Sentiment Score

84

Actual DrawDown %

98.4

Max Drawdown 5-Year %

-98.4

Target Price

7

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

-0.86

Average EPS Est. Cur. Y​

-0.33

EPS Next Y. (Est.)

-0.09

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.53

Return on Equity vs Sector %

594.5

Return on Equity vs Industry %

607.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

21.1
Iterum Therapeutics plc
Sector: Healthcare
Industry: Biotechnology
Employees: 9
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
stock quote shares ITRM – Iterum Therapeutics Plc Stock Price stock today
news today ITRM – Iterum Therapeutics Plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ITRM – Iterum Therapeutics Plc yahoo finance google finance
stock history ITRM – Iterum Therapeutics Plc invest stock market
stock prices ITRM premarket after hours
ticker ITRM fair value insiders trading

AMRN – Amarin Corp ADR

Float Short %

2.06

Margin Of Safety %

Put/Call OI Ratio

0.28

EPS Next Q Diff

-0.09

EPS Last/This Y

4.2

EPS This/Next Y

-0.05

Price

15

Target Price

11

Analyst Recom

4.33

Performance Q

12.18

Relative Volume

0.46

Beta

0.61

Ticker: AMRN




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15AMRN15.690.310.3210158
2025-08-18AMRN16.160.270.238651
2025-08-19AMRN15.930.271.528899
2025-08-20AMRN15.840.272.678957
2025-08-21AMRN15.870.280.079004
2025-08-22AMRN16.040.280.129024
2025-08-25AMRN15.40.280.819043
2025-08-26AMRN15.610.280.159053
2025-08-27AMRN15.410.280.509072
2025-08-28AMRN15.450.280.929078
2025-08-29AMRN15.050.282.529096
2025-09-02AMRN15.170.290.509197
2025-09-03AMRN150.290.249214
2025-09-04AMRN14.940.291.919230
2025-09-05AMRN15.250.290.009257
2025-09-08AMRN14.760.290.159358
2025-09-09AMRN15.260.290.219417
2025-09-10AMRN15.060.283.139510
2025-09-11AMRN14.950.280.489537
2025-09-12AMRN150.280.809560
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15AMRN15.59100.0- 0.20
2025-08-18AMRN16.21100.0- 0.20
2025-08-19AMRN15.82100.0- 0.20
2025-08-20AMRN15.87100.0- 0.20
2025-08-21AMRN15.87100.0- 0.20
2025-08-22AMRN16.05100.0- 0.20
2025-08-25AMRN15.44100.0- 0.20
2025-08-26AMRN15.54100.0- 0.20
2025-08-28AMRN15.40100.0- 0.20
2025-08-29AMRN15.05100.0- 0.20
2025-09-02AMRN15.18100.0- 0.20
2025-09-03AMRN15.04100.0- 0.20
2025-09-04AMRN15.04100.0- 0.20
2025-09-05AMRN15.33100.0- 0.20
2025-09-08AMRN14.77100.0- 0.20
2025-09-09AMRN15.20100.0- 0.20
2025-09-10AMRN15.06100.0- 0.20
2025-09-11AMRN14.97100.0- 0.20
2025-09-12AMRN15.00100.0- 0.20
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15AMRN0.008.853.02
2025-08-18AMRN0.00-3.192.30
2025-08-19AMRN0.00-3.192.30
2025-08-20AMRN0.00-3.192.30
2025-08-21AMRN0.00-3.192.30
2025-08-22AMRN0.00-3.192.30
2025-08-25AMRN0.001.132.30
2025-08-26AMRN0.001.132.30
2025-08-27AMRN0.001.132.06
2025-08-28AMRN0.001.132.06
2025-08-29AMRN0.001.132.06
2025-09-02AMRN0.001.132.06
2025-09-03AMRN0.001.132.06
2025-09-04AMRN0.001.132.06
2025-09-05AMRN0.001.132.06
2025-09-08AMRN0.001.132.06
2025-09-09AMRN0.001.132.06
2025-09-10AMRN0.001.132.06
2025-09-11AMRN0.001.132.06
2025-09-12AMRN0.001.132.06
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.03

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

-0.12

Insider Transactions

Institutional Transactions

1.13

Beta

0.61

Average Sales Estimate Current Quarter

42

Average Sales Estimate Next Quarter

41

Fair Value

Quality Score

33

Growth Score

23

Sentiment Score

67

Actual DrawDown %

91.9

Max Drawdown 5-Year %

-95.5

Target Price

11

P/E

Forward P/E

PEG

P/S

1.42

P/B

0.67

P/Free Cash Flow

EPS

-5.03

Average EPS Est. Cur. Y​

0.2

EPS Next Y. (Est.)

0.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-47.05

Relative Volume

0.46

Return on Equity vs Sector %

-47.2

Return on Equity vs Industry %

-55.7

EPS 1 7Days Diff

2.2

EPS 1 30Days Diff

2.21

EBIT Estimation

Amarin Corporation plc
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 275
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
stock quote shares AMRN – Amarin Corp ADR Stock Price stock today
news today AMRN – Amarin Corp ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch AMRN – Amarin Corp ADR yahoo finance google finance
stock history AMRN – Amarin Corp ADR invest stock market
stock prices AMRN premarket after hours
ticker AMRN fair value insiders trading

ALKS – Alkermes plc

Float Short %

8.28

Margin Of Safety %

1

Put/Call OI Ratio

0.88

EPS Next Q Diff

-0.12

EPS Last/This Y

-0.47

EPS This/Next Y

-0.22

Price

26.96

Target Price

41.59

Analyst Recom

1.65

Performance Q

-12.38

Relative Volume

1.27

Beta

0.53

Ticker: ALKS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15ALKS29.060.600.3027952
2025-08-18ALKS28.110.471.4415206
2025-08-19ALKS28.850.500.3015719
2025-08-20ALKS28.980.503.0915817
2025-08-21ALKS29.070.555.6316544
2025-08-22ALKS29.760.560.2416718
2025-08-25ALKS28.990.553.3916959
2025-08-26ALKS28.990.60144.8017897
2025-08-27ALKS29.250.650.3818511
2025-08-28ALKS28.930.650.7418522
2025-08-29ALKS28.970.673.0018667
2025-09-02ALKS29.420.687.0318897
2025-09-03ALKS29.960.701.0619237
2025-09-04ALKS28.930.801.1222993
2025-09-05ALKS29.950.812.6824379
2025-09-08ALKS28.440.861.1125821
2025-09-09ALKS27.830.757.0731681
2025-09-10ALKS26.910.881.3034130
2025-09-11ALKS27.720.880.2234160
2025-09-12ALKS26.970.881.5834238
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15ALKS29.06-47.1-94.01.73
2025-08-18ALKS28.11-47.1-117.91.73
2025-08-19ALKS28.85-47.1-94.81.73
2025-08-20ALKS28.98-47.1-103.41.73
2025-08-21ALKS29.07-47.1-103.81.73
2025-08-22ALKS29.76-47.1-95.61.73
2025-08-25ALKS28.99-47.1-115.21.73
2025-08-26ALKS28.98-47.1-105.41.73
2025-08-28ALKS28.93-47.1-109.51.73
2025-08-29ALKS28.96-47.1-104.81.73
2025-09-02ALKS29.40-47.1-99.31.73
2025-09-03ALKS30.01-47.1-88.61.73
2025-09-04ALKS28.92-47.1-111.51.73
2025-09-05ALKS29.94-47.1-82.71.73
2025-09-08ALKS28.45-47.4-116.91.70
2025-09-09ALKS27.84-47.1-105.71.73
2025-09-10ALKS26.93-47.3-110.51.75
2025-09-11ALKS27.71-47.3-85.11.75
2025-09-12ALKS26.96-47.3-108.11.75
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15ALKS-0.372.368.56
2025-08-18ALKS-0.37-1.518.60
2025-08-19ALKS-0.31-1.518.60
2025-08-20ALKS-0.31-1.518.60
2025-08-21ALKS-0.28-1.518.60
2025-08-22ALKS-0.28-1.518.60
2025-08-25ALKS-0.28-2.048.60
2025-08-26ALKS-0.20-2.048.60
2025-08-27ALKS-0.20-2.048.59
2025-08-28ALKS-0.20-2.048.59
2025-08-29ALKS-0.20-2.048.59
2025-09-02ALKS-0.15-2.038.59
2025-09-03ALKS-0.15-2.038.59
2025-09-04ALKS-0.15-2.038.59
2025-09-05ALKS-0.15-2.038.59
2025-09-08ALKS-0.15-2.058.59
2025-09-09ALKS-0.15-2.058.59
2025-09-10ALKS-0.15-2.058.59
2025-09-11ALKS-0.15-2.058.28
2025-09-12ALKS-0.15-2.058.28
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

0.38

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

-0.15

Institutional Transactions

-2.05

Beta

0.53

Average Sales Estimate Current Quarter

355

Average Sales Estimate Next Quarter

366

Fair Value

27.32

Quality Score

99

Growth Score

40

Sentiment Score

5

Actual DrawDown %

26

Max Drawdown 5-Year %

-33.2

Target Price

41.59

P/E

12.95

Forward P/E

17.21

PEG

P/S

2.96

P/B

2.74

P/Free Cash Flow

9.28

EPS

2.08

Average EPS Est. Cur. Y​

1.75

EPS Next Y. (Est.)

1.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

23.15

Relative Volume

1.27

Return on Equity vs Sector %

-3.4

Return on Equity vs Industry %

13.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-108.1
Alkermes plc
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1800
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
stock quote shares ALKS – Alkermes plc Stock Price stock today
news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALKS – Alkermes plc yahoo finance google finance
stock history ALKS – Alkermes plc invest stock market
stock prices ALKS premarket after hours
ticker ALKS fair value insiders trading

TT – Trane Technologies plc

Float Short %

1.33

Margin Of Safety %

-9

Put/Call OI Ratio

0.58

EPS Next Q Diff

-0.94

EPS Last/This Y

1.75

EPS This/Next Y

1.64

Price

400.44

Target Price

468.63

Analyst Recom

2.67

Performance Q

-5.55

Relative Volume

1.22

Beta

1.12

Ticker: TT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15TT423.420.620.1411827
2025-08-18TT428.990.621.029672
2025-08-19TT428.890.620.109798
2025-08-20TT4260.620.319863
2025-08-21TT422.30.630.089882
2025-08-22TT424.180.620.569983
2025-08-25TT419.510.620.8810032
2025-08-26TT426.050.621.3810040
2025-08-27TT424.10.620.0110063
2025-08-28TT424.580.620.3110032
2025-08-29TT415.610.610.5610166
2025-09-02TT410.720.620.6910241
2025-09-03TT408.30.620.4110360
2025-09-04TT413.140.630.2010413
2025-09-05TT414.180.590.2810805
2025-09-08TT415.160.580.9110815
2025-09-09TT409.320.580.1610861
2025-09-10TT417.130.570.5211129
2025-09-11TT415.060.580.3811120
2025-09-12TT400.480.581.8011204
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15TT423.3713.7114.113.10
2025-08-18TT429.1313.7211.213.10
2025-08-19TT428.7913.7159.213.10
2025-08-20TT425.9713.7135.013.10
2025-08-21TT422.3013.7124.313.10
2025-08-22TT424.0613.7176.113.10
2025-08-25TT419.5613.7119.113.10
2025-08-26TT426.1913.7219.513.10
2025-08-27TT424.0413.7140.813.10
2025-08-28TT424.6013.7163.713.10
2025-08-29TT415.1213.775.813.10
2025-09-02TT410.6313.7114.513.10
2025-09-03TT408.0813.7490.613.10
2025-09-04TT413.0813.7567.813.10
2025-09-05TT413.8313.7526.213.10
2025-09-08TT414.9313.7530.413.10
2025-09-09TT409.3613.7463.613.10
2025-09-10TT417.2013.7598.313.10
2025-09-11TT414.8813.7495.113.10
2025-09-12TT400.4413.7374.913.10
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15TT-4.622.171.47
2025-08-18TT-4.620.861.47
2025-08-19TT-9.470.861.47
2025-08-20TT-9.470.861.47
2025-08-21TT-9.470.861.47
2025-08-22TT-9.470.861.47
2025-08-25TT-9.470.921.47
2025-08-26TT-8.830.921.47
2025-08-27TT-8.830.921.36
2025-08-28TT-8.830.921.36
2025-08-29TT-8.830.921.36
2025-09-02TT-8.830.811.36
2025-09-03TT-11.840.811.36
2025-09-04TT-11.840.811.36
2025-09-05TT-11.840.811.36
2025-09-08TT-5.430.471.36
2025-09-09TT-5.430.471.36
2025-09-10TT-5.430.471.36
2025-09-11TT-5.430.471.33
2025-09-12TT-5.430.471.33
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

3.88

Avg. EPS Est. Current Quarter

3.83

Avg. EPS Est. Next Quarter

2.94

Insider Transactions

-5.43

Institutional Transactions

0.47

Beta

1.12

Average Sales Estimate Current Quarter

5844

Average Sales Estimate Next Quarter

5307

Fair Value

364.87

Quality Score

93

Growth Score

95

Sentiment Score

96

Actual DrawDown %

15.9

Max Drawdown 5-Year %

-40.5

Target Price

468.63

P/E

31.8

Forward P/E

27.25

PEG

2.3

P/S

4.3

P/B

11.39

P/Free Cash Flow

31.78

EPS

12.6

Average EPS Est. Cur. Y​

13.1

EPS Next Y. (Est.)

14.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.76

Relative Volume

1.22

Return on Equity vs Sector %

19.2

Return on Equity vs Industry %

17.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

374.9
Trane Technologies plc
Sector: Industrials
Industry: Building Products & Equipment
Employees: 45000
Trane Technologies plc designs, manufactures, sells, and services of solutions for heating, ventilation, air conditioning, and custom and transport refrigeration. It offers air conditioners, exchangers, and handlers; airside and terminal devices; air sourced heat pumps; chillers; coils and condensers; auxiliary power, cold storage, cold storage, and condensing units; controls contracting and commissioning, decarbonization programs, and gensets; dehumidifiers; energy and water efficiency programs; energy recovery ventilators; energy storage; furnaces; home automation; humidifiers; HVAC performance-monitoring products; and indoor air quality assessments and related products for HVAC and transport solutions. The company also provides asset management, building management, bus air purification, bus and rail HVAC, container refrigeration, control, cryogenic refrigeration, ductless, geothermal, data center and multi-pipe HVAC, package heating and cooling, rail refrigeration, residential air filtration, self-powered truck refrigeration, temporary heating and cooling, truck refrigeration, unitary, variable refrigerant flow, and trailer refrigeration systems. In addition, it offers industrial process refrigeration, installation contracting, lighting retrofit, medical grade refrigeration, refrigerant reclamation, renewable energy and storage, residential hybrid heating, telematics, thermostats/controls and associated digital, and ventilation solutions; packaged rooftop units; rate chambers; residential air filters; thermal energy storage; transport heater products; ultra-low temperature freezers; energy infrastructure programs and management, repair and maintenance, smart and AI-enabled, and rental services; and water source heat pumps, as well as aftermarket and OEM parts and supplies. The company was formerly known as Ingersoll-Rand Plc and changed its name to Trane Technologies plc in March 2020. The company was founded in 1885 and is headquartered in Swords, Ireland.
stock quote shares TT – Trane Technologies plc Stock Price stock today
news today TT – Trane Technologies plc stock forecast ,stock prediction 2023 2024 2025
marketwatch TT – Trane Technologies plc yahoo finance google finance
stock history TT – Trane Technologies plc invest stock market
stock prices TT premarket after hours
ticker TT fair value insiders trading
No more stocks to show